-
From evidence-based medicine to personalized medicine in Crohn?s disease
Louis E. , Reenaers C. , Van Kemseke C. , Latour P. , Belaiche J. , Meunier P. , Coïmbra C.
Rev Med Liege 2015, 70(5-6),316-320Abstract : The therapeutic armamentarium in Crohn's disease includes mesalazine, steroids (including topical drugs), anti-metabolites (purines, methotrexate), anti-TNFalpha antibodies and, more recently, selective inhibitors of lymphocytes homing (vedolizumab). The efficacy of these drugs has been shown in pivotal phase 3 placebo-controlled trials and meta-analyses. However, the use of these drugs in routine practice still remains ill-defined. Those are rather the cohort studies, natural history data and therapeutic strategy trials that help the clinician to determine, for each individual patient, the treatment leading to an optimal benefit/risk profile, aiming at moving from evidence-based medicine towards personalized medicine.
